Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy
BackgroundThe purpose of this study was set to investigate the prognostic role of plasmatic levels of heat shock protein 90 alpha (HSP90α) at diagnosis in advanced lung cancer patients treated with Programmed cell death protein 1 (PD-1)/Programmed cell death-Ligand protein 1 (PD-L1) inhibitors plus...
Saved in:
Main Authors: | Shubin Chen, Qitao Yu, Shaozhang Zhou |
---|---|
Format: | article |
Language: | EN |
Published: |
Frontiers Media S.A.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/c7c859bebc814d268df00627ae90fe83 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
by: Yixi Zhang, et al.
Published: (2021) -
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
by: Zhitao Li, et al.
Published: (2021) -
Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy
by: Jing Zhou, et al.
Published: (2022) -
Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression
by: Chang-Jin Jung, et al.
Published: (2021) -
Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
by: Olga V. Kovaleva, et al.
Published: (2021)